Àΰø½ÉÀåÆÇ¸· ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : ¹ëºêº°, ¼ÒÀ纰, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹® ¿¹Ãø(2025-2033³â)
Prosthetic Heart Valve Market Size, Share & Trends Analysis Report By Valve (Transcatheter Heart Valves, Bioprosthetic Valves, Mechanical Valves), By Material, By End-use, By Region, And Segment Forecasts, 2025 - 2033
»óǰÄÚµå : 1813791
¸®¼­Ä¡»ç : Grand View Research
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 150 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,431,000
Unprintable PDF & Excel (Single User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» 1Àθ¸ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,950 £Ü 9,848,000
Printable PDF & Excel (5-User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ ºÎ¼­¿¡¼­ ÃÖ´ë 5¸í±îÁö »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,683,000
Printable PDF & Excel (Enterprise License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷(ÀÚȸ»ç Æ÷ÇÔ)ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù. Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â ÆÄÀÏÀÇ ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Àΰø½ÉÀåÆÇ¸· ½ÃÀå ¿ä¾à

Àΰø½ÉÀåÆÇ¸· ¼¼°è ½ÃÀå ±Ô¸ð´Â 2024³â 96¾ï 4,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2025-2033³â ¿¬Æò±Õ 8.7% ¼ºÀåÇÏ¿© 2033³â¿¡´Â 206¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

½ÉÀåÆÇ¸·Áõ Áõ°¡°¡ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÔ´Ï´Ù.

2024³â 12¿ù¿¡ ¹ßÇ¥µÈ NCBIÀÇ ³í¹®¿¡ µû¸£¸é, ÃÖ±Ù ÃßÁ¤¿¡ µû¸£¸é ¾à 5,480¸¸ ¸íÀÌ ·ù¸¶Æ¼½º¼º ½ÉÀ庴(RHD)À» ¾Î°í ÀÖÀ¸¸ç, ±× ½Å·Ú ¹üÀ§´Â 4,330¸¸ ¸í¿¡¼­ 6,760¸¸ ¸í¿¡ ´ÞÇÑ´Ù°í ÇÕ´Ï´Ù. ¶ÇÇÑ, ºñ·ù¸¶Æ¼½º¼º ¼®È¸Ä§Âø¼º ´ëµ¿¸ÆÆÇ¸·Áúȯ(CAVD)Àº ¾à 1,330¸¸ ¸í¿¡°Ô ¿µÇâÀ» ¹ÌÄ¡¸ç, ºñ·ù¸¶Æ¼½º¼º ÅðÇ༺ ½Â¸ðÆÇ¸·Áúȯ(DMVD)Àº Àü ¼¼°èÀûÀ¸·Î ¾à 1,550¸¸ ¸í¿¡°Ô ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÁúȯÀº ±¸Á¶Àû ÆÇ¸· ±â´É ÀúÇÏÀÇ ÁÖ¿ä ¿øÀÎ Áß ÇϳªÀ̸ç, Á¾Á¾ ¿Ü°úÀû ¶Ç´Â °æÄ«Å×ÅÍ ÆÇ¸· ġȯ¼úÀÌ ÇÊ¿äÇÕ´Ï´Ù. ¶ÇÇÑ, ´Ù¾çÇÑ ¿¬·É´ë¿Í Áö¿ª¿¡¼­ ·ù¸¶Æ¼½º¼º ÆÇ¸·Áúȯ°ú ÅðÇ༺ ÆÇ¸·ÁúȯÀÇ ³ôÀº À¯º´·ü°ú Áõ°¡ Ãß¼¼´Â ½ÃÀå È®´ë¸¦ ÃËÁøÇÏ´Â Áß¿äÇÑ ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

ƯÈ÷ ³ë³âÃþ¿¡¼­ ½ÉÀåÆÇ¸· ÁúȯÀÇ ¹ßº´·ü Áõ°¡´Â ¼ö¼úÀû Á¢±Ù ¹æ½Ä°ú Ä«Å×ÅÍ Á¢±Ù ¹æ½ÄÀ» Æ÷ÇÔÇÑ Àΰø½ÉÀåÆÇ¸· ġȯ¼úÀÇ Ã¤ÅÃÀÌ È®´ëµÇ°í ÀÖ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ´ëµ¿¸ÆÆÇ¸·ÇùÂøÁõ, ½Â¸ðÆÇ¸·Æó¼âºÎÀüÁõ°ú °°Àº ÅðÇ༺ ÁúȯÀº Á¡Á¡ ´õ ³Î¸® ÆÛÁö°í ÀÖÀ¸¸ç, ÀΰøÆÇ¸· ÀÓÇöõÆ®¿Í °°Àº È¿°úÀûÀÎ °³ÀÔÀÇ Çʿ伺ÀÌ ´ëµÎµÇ°í ÀÖ½À´Ï´Ù. 2024³â¿¡ ¹ßÇ¥µÈ CDCÀÇ ³í¹®¿¡ µû¸£¸é, ¹Ì±¹ ¼ºÀÎ 4¸í Áß 3¸íÀº ½ÉÀåÆÇ¸·Áõ¿¡ ´ëÇÑ ÀνÄÀÌ ³·À¸¸ç, ƯÈ÷ 65¼¼ ÀÌ»óÀÇ ÀνÄÀÌ ³·Àº °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ¸Å³â 500¸¸ ¸í ÀÌ»óÀÇ ¹Ì±¹ÀÎÀÌ ½ÉÀåÆÇ¸·Áõ Áø´ÜÀ» ¹Þ°í, ¸Å³â 25,000¸í ÀÌ»óÀÌ »ç¸ÁÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¼öÄ¡´Â ±³À° °³¼±, Á¶±â Áø´Ü, Àΰø½ÉÀåÆÇ¸· Ä¡·á¿¡ ´ëÇÑ Á¢±Ù¼º È®´ë°¡ ½Ã±ÞÇÏ´Ù´Â °ÍÀ» °­Á¶Çϰí ÀÖ½À´Ï´Ù.

Á¤ºÎÀÇ ÀçÁ¤Àû Áö¿ø°ú ÀÎ½Ä °³¼± Ä·ÆäÀÎÀº Àΰø½ÉÀåÆÇ¸· »ê¾÷ÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. 2024³â 10¿ù¿¡ ¹ßÇ¥µÈ ¹Ì±¹½ÉÀåÇùȸ(American Heart Association, Inc.)ÀÇ ±â»ç¿¡ µû¸£¸é, CDC´Â ½ÉÀåÆÇ¸·Áõ ±³À°¿¡ ÃÊÁ¡À» ¸ÂÃá Àü±¹ÀûÀÎ Ä·ÆäÀÎÀ» ½ÃÀÛÇϱâ À§ÇØ ¹Ì±¹½ÉÀåÇùȸ¿¡ 840¸¸ ´Þ·¯ÀÇ º¸Á¶±ÝÀ» ¼ö¿©Çß½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÌ´Ï¼ÅÆ¼ºê¿¡´Â ȯÀÚ, ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü ¹× °íÀ§Ç豺ÀÎ ¿©¼ºµéÀ» ´ë»óÀ¸·Î ÇÑ ±³À°Àû ¾Æ¿ô¸®Ä¡ Ȱµ¿ÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ ÇÁ·Î±×·¥Àº 2022³â 12¿ù¿¡ ¼­¸íµÈ HVDÀÇ ¿¬±¸¿Í ÀÎÁöµµ¸¦ ¿ì¼±½ÃÇÏ´Â ÃÊ´çÀû Á¶»ç¹ý(CAROL Act)¿¡¼­ ºñ·ÔµÇ¾ú½À´Ï´Ù.

°æÇÇÀû Ä«Å×ÅÍ ÆÇ¸· ġȯ¼ú(TAVR)À» Æ÷ÇÔÇÑ ÃÖ¼Ò Ä§½À ¼ö¼úÀº ±âÁ¸ °³½É¼ú¿¡ ºñÇØ ȸº¹ ½Ã°£ÀÌ Âª°í, ÇÕº´Áõ À§ÇèÀÌ ÀûÀ¸¸ç, Àüü ÀÇ·áºñ¿ëÀ» Àý°¨ÇÒ ¼ö ÀÖ¾î ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºñħ½ÀÀû ¼ö¼ú·ÎÀÇ ÀüȯÀº ½ÃÀåÀ» ÁÖµµÇÏ´Â Áß¿äÇÑ ¿ä¼ÒÀÔ´Ï´Ù. 2024³â 4¿ù, Abbott´Â »ï÷ÆÇ¸·Æó¼âºÎÀüÁõ(TR) Ä¡·á¸¦ À§ÇÑ °æÄ«Å×ÅÍ½Ä ¿§Áö Åõ ¿§Áö(edge-to-edge) ¼ö¸® ±â¼úÀÎ TriClip ½Ã½ºÅÛÀÇ FDA ½ÂÀÎÀ» ¹ßÇ¥ÇÏ¿´½À´Ï´Ù. ÀÌ ¼¼°è ÃÖÃÊÀÇ ÀåÄ¡´Â Àúħ½ÀÀû Ä¡·á¸¦ °¡´ÉÇÏ°Ô ÇÏ¿© °íÀ§Çè °³½É¼ú ¾øÀ̵µ ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÒ ¼ö ÀÖ´Â ¼¼°è ÃÖÃÊÀÇ ÀåÄ¡ÀÔ´Ï´Ù. ÀÓ»ó½ÃÇè¿¡¼­ TriClipÀ» »ç¿ëÇÑ È¯ÀÚÀÇ TR ÁßÁõµµ ¹× »îÀÇ ÁúÀÌ À¯ÀǹÌÇÏ°Ô °³¼±µÈ °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù.

¹ëºêÀÇ ³»±¸¼º Çâ»ó, ÀÌ½Ä ¿ëÀ̼º, ȯÀÚ ¿¹ÈÄ °³¼± µî °æ Ä«Å×ÅÍ ½ÉÀåÆÇ¸·(THV) ¼³°èÀÇ ±â¼úÀû Áøº¸°¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¿µ»óó¸® ±â¼ú°ú ¹ëºê Àü´Þ ½Ã½ºÅÛÀÇ ¹ßÀüµµ ½Ã¼ú ¼º°ø·üÀ» Å©°Ô Çâ»ó½ÃÄÑ THV ½Ã¼úÀÇ ´ë»ó ȯÀÚÃþÀ» È®´ëÇÒ ¼ö ÀÖ½À´Ï´Ù. 2024³â 8¿ù, º¸½ºÅÏ »çÀ̾ðƼÇÈÀº ACURATE Prime Aortic Valve SystemÀÌ CE ¸¶Å© ½ÂÀÎÀ» ȹµæÇß´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ ÃÖ÷´Ü °æ Ä«Å×ÅÍ ´ëµ¿¸Æ ÆÇ¸· ġȯ¼ú ½Ã½ºÅÛÀº ´õ Å« °ñ°ÝÀÇ È¯ÀÚ¸¦ ¼ö¿ëÇÒ ¼ö ÀÖµµ·Ï »õ·Î¿î ÆÇ¸· Å©±â¸¦ Ư¡À¸·Î ÇÕ´Ï´Ù. ÁßÁõ ´ëµ¿¸ÆÆÇ¸· ÇùÂøÁõÀ» ¾Î°í ÀÖ´Â ÀúÀ§Çè, ÁßÀ§Çè, °íÀ§Ç豺 ȯÀÚ¿¡°Ô ÀûÀÀÁõÀÌ ÀÖ½À´Ï´Ù. ÀÌ ½Ã½ºÅÛÀº ÀÚü È®ÀåÇü ¼³°è¿Í Á¤±³ÇÑ Àü°³ ¸ÞÄ¿´ÏÁòÀ» ÅëÇÕÇÏ¿© ¹ëºêÀÇ À§Ä¡ °áÁ¤ Á¤È®µµ¸¦ ³ô¿© Àüü ȯÀÚ °á°ú¸¦ °³¼±ÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¼¼°èÀÇ Àΰø½ÉÀåÆÇ¸· ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå ¼¼°èÀÇ Àΰø½ÉÀåÆÇ¸· ½ÃÀå ºÎ¹® ºÐ¼®, ¹ëºêº°, 2021³â-2033³â

Á¦5Àå ¼¼°èÀÇ Àΰø½ÉÀåÆÇ¸· ½ÃÀå ºÎ¹® ºÐ¼®, ¼ÒÀ纰, 2021³â-2033³â

Á¦6Àå ¼¼°èÀÇ Àΰø½ÉÀåÆÇ¸· ½ÃÀå ºÎ¹® ºÐ¼®, ÃÖÁ¾ ¿ëµµº°, 2021³â-2033³â

Á¦7Àå Àΰø½ÉÀåÆÇ¸· ½ÃÀå ºÎ¹® ºÐ¼®, Áö¿ªº°, 2021³â-2033³â

Á¦8Àå °æÀï ±¸µµ

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Prosthetic Heart Valve Market Summary

The global prosthetic heart valve market size was estimated at USD 9.64 billion in 2024 and is projected to reach USD 20.69 billion by 2033, growing at a CAGR of 8.7% from 2025 to 2033. Rising valvular heart diseases drive the growth of the market.

According to an NCBI article published in December 2024, recent estimates indicate that approximately 54.8 million people are affected by rheumatic heart disease (RHD), with a confidence range between 43.3 and 67.6 million. In addition, non-rheumatic calcific aortic valve disease (CAVD) impacts around 13.3 million individuals, while non-rheumatic degenerative mitral valve disease (DMVD) accounts for approximately 15.5 million cases globally. These conditions are among the leading causes of structural valve deterioration, often necessitating surgical or transcatheter valve replacement. Moreover, the high and growing prevalence of both rheumatic and degenerative valve disorders across diverse age groups and regions is a key factor propelling the expansion of the market.

The rising incidence of heart valve disorders, particularly among the elderly, is a key driver for the growing adoption of prosthetic heart valve procedures, including both surgical and transcatheter approaches. Degenerative conditions such as aortic stenosis and mitral regurgitation are becoming increasingly prevalent, prompting the need for effective interventions like prosthetic valve implants. According to the CDC article published in 2024, three in four adults in the U.S. have limited awareness of heart valve disease, with particularly low recognition among those aged 65 and older, ironically, the group most at risk. Annually, more than 5 million Americans are diagnosed with heart valve disease, and the condition is responsible for over 25,000 deaths each year. These figures underscore a pressing need for improved education, early diagnosis, and expanded access to prosthetic heart valve therapies.

Government funding and awareness campaigns fuel growth in the prosthetic heart valve industry. According to the American Heart Association, Inc., an article published in October 2024, the CDC awarded USD 8.4 million in grants to the American Heart Association to launch national campaigns focused on heart valve disease education. These initiatives will include educational outreach targeting patients, healthcare providers, and women, an underserved high-risk group. The program stems from the bipartisan CAROL Act, signed into law in December 2022, to prioritize HVD research and awareness.

There is an increasing demand for minimally invasive surgeries, including transcatheter valve replacement (TAVR), due to their shorter recovery times, reduced complication risks, and lower overall healthcare costs than traditional open-heart surgery. This shift towards non-invasive procedures is a critical factor propelling the market. In April 2024, Abbott announced FDA approval for its TriClip system, a transcatheter edge-to-edge repair technology for treating tricuspid regurgitation (TR). This first-of-its-kind device allows for less invasive treatment, improving patient outcomes without needing high-risk open-heart surgery. Clinical trials showed significant improvements in TR severity and quality of life for patients treated with TriClip.

Technological advancements in Transcatheter Heart Valves (THV) design, such as enhanced valve durability, ease of implantation, and better patient outcomes, are key drivers driving market growth. Advancements in imaging techniques and valve delivery systems also significantly improve procedural success and expand the patient pool eligible for THV procedures. In August 2024, Boston Scientific announced that its ACURATE Prime Aortic Valve System received CE mark approval. This state-of-the-art transcatheter aortic valve replacement system features a new valve size to serve patients with larger anatomies. It is indicated for individuals at low, intermediate, and high risk experiencing severe aortic stenosis. The system incorporates a self-expanding design and a refined deployment mechanism, enhancing valve positioning accuracy to improve overall patient outcomes.

Global Prosthetic Heart Valve Market Report Segmentation

This report forecasts revenue growth and analyzes the latest trends in each sub-segments from 2021 to 2033 at the global, regional, and country levels. For this report, Grand View Research has segmented the global prosthetic heart valve market report based on valve, material, end-use, and region:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Global Prosthetic Heart Valve Market Variables, Trends & Scope

Chapter 4. Global Prosthetic Heart Valve Market Segment Analysis, By Valve, 2021 - 2033 (USD Million)

Chapter 5. Global Prosthetic Heart Valve Market Segment Analysis, By Material, 2021 - 2033 (USD Million)

Chapter 6. Global Prosthetic Heart Valve Market Segment Analysis, By End Use, 2021 - 2033 (USD Million)

Chapter 7. Prosthetic Heart Valve Market Segment Analysis, By Region, 2021- 2033 (USD Million)

Chapter 8. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â